MILWAUKEE, Nov. 17, 2015 (GLOBE NEWSWIRE) --
We are investigating possible securities fraud claims against Clovis resulting from inaccurate statements Clovis made regarding its financial performance.
Click here to learn more about the investigation: http://www.ademilaw.com/case/clovis or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Our investigation focuses on the extent to which Clovis issued false and misleading statements regarding its past and future business performance and prospects. Specifically, the investigation is related to Clovis’ disclosure that its lead drug candidate rociletinib is less effective than previously presented, resulting in the delay of regulatory approval of its drug because the FDA has asked for more data. Clovis also admitted that it knew of this lower effectiveness since the end of October.
If you wish to obtain additional information or have information about Clovis, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, http://www.ademilaw.com/case/clovis.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.